{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-08T20:01:05.155441+00:00","company":{"ticker":"GNPX","cik":1595248,"company_name":"Genprex, Inc."},"pagination":{"limit":100,"returned":24,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"H.C. Wainwright & Co., LLC","detail":"atm_program","count":1,"first_seen":"2023-12-13T23:59:59+00:00","last_seen":"2023-12-13T23:59:59+00:00","evidence_fact_ids":[88590]},{"display_name":"JMP Securities LLC","detail":"atm_program","count":1,"first_seen":"2023-12-13T23:59:59+00:00","last_seen":"2023-12-13T23:59:59+00:00","evidence_fact_ids":[88591]}]},"facts":[{"fact_type":"exchange_compliance_notice","fact_key":"649a725afc137bb255899bd146df42a78e63d2cc","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-11-26T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2025-12-31","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-11-25","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"Genprex, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"November 25, 2025, the Company was formally notified that (i) the Panel determined that the Company has regained compliance with the Bid Price Requirement; and (ii) the Panel has also approved the Company’s request for an exception until December 31, 2025 to demonstrate long-term compliance with the Stockholders’ Equity Requirement (as extended, the “Exception”). As previously disclosed, upon request by the Company, the Panel has discretion to grant the Company continued listing through February 9, 2026.  Pursuant to the Exception, the Company is required to, and fully intends to, provide the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-036380","anchor_url":"https://secwatch.observer/filing/0001437749-25-036380#claim-649a725afc137bb255899bd146df42a78e63d2cc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925036380/0001437749-25-036380-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"4b37bed6eb9b2c9197b1d49fe381c6eb62ac3dec","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-11-26T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-11-25","notice_type":"compliance_regained","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"Genprex, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"November 25, 2025, the Company was formally notified that (i) the Panel determined that the Company has regained compliance with the Bid Price Requirement; and (ii) the Panel has also approved the Company’s request for an exception until December 31, 2025 to demonstrate long-term compliance with the Stockholders’ Equity Requirement (as extended, the “Exception”). As previously disclosed, upon request by the Company, the Panel has discretion to grant the Company continued listing through February 9, 2026.  Pursuant to the Exception, the Company is required to, and fully intends to, provide the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-036380","anchor_url":"https://secwatch.observer/filing/0001437749-25-036380#claim-4b37bed6eb9b2c9197b1d49fe381c6eb62ac3dec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925036380/0001437749-25-036380-index.htm"},{"fact_type":"equity_issuance","fact_key":"cd7d8b4e335bc2c420d97417e2c9870d0a417f72","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-10-29T23:59:59+00:00","payload":{"action":"pipe","consideration_text":null,"effective_date":null,"item_codes_triggered":["3.02"],"purchaser":"certain investors named therein (the \"Purchasers\")","security_type":"warrant","shares_text":"up to an aggregate of 755,560 shares of Common Stock"},"claim":"Genprex, Inc. issued up to an aggregate of 755,560 shares of Common Stock of warrant to certain investors named therein (the \"Purchasers\").","evidence_excerpt":"the Company agreed to issue to the Purchasers warrants (the \"Private Warrants\") exercisable for up to an aggregate of 755,560 shares of Common Stock (the \"Private Warrant Shares\")","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-032081","anchor_url":"https://secwatch.observer/filing/0001437749-25-032081#claim-cd7d8b4e335bc2c420d97417e2c9870d0a417f72","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925032081/0001437749-25-032081-index.htm"},{"fact_type":"equity_issuance","fact_key":"77b8ed0660995bce62f44e79eac7d18151d3a7f7","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-10-24T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":null,"effective_date":"2025-10-23","item_codes_triggered":["3.02"],"purchaser":"certain investors named in the Purchase Agreement","security_type":"warrant","shares_text":"up to an aggregate of 487,244 shares of Common Stock"},"claim":"Genprex, Inc. issued up to an aggregate of 487,244 shares of Common Stock of warrant to certain investors named in the Purchase Agreement.","evidence_excerpt":"the Company agreed to issue to the Purchasers warrants (the “Private Warrants”) exercisable for up to an aggregate of 487,244 shares of Common Stock (the “Private Warrant Shares”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-031678","anchor_url":"https://secwatch.observer/filing/0001437749-25-031678#claim-77b8ed0660995bce62f44e79eac7d18151d3a7f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925031678/0001437749-25-031678-index.htm"},{"fact_type":"governance_change","fact_key":"5724e42a3a5eb0b90ef3af4f69aba87840ac5116","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-10-17T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-10-21","item_codes_triggered":["5.03"],"summary_text":"Certificate of Amendment to effect a one-for-fifty reverse stock split"},"claim":"Genprex, Inc.: Certificate of Amendment to effect a one-for-fifty reverse stock split (effective 2025-10-21).","evidence_excerpt":"On October 16, 2025, Genprex filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time on October 21, 2025, a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-031210","anchor_url":"https://secwatch.observer/filing/0001437749-25-031210#claim-5724e42a3a5eb0b90ef3af4f69aba87840ac5116","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"50cc24aac74dfda4772112233a837047c46d3599","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-10-17T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-08-19","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":[],"rules_cited_in_text":false},"claim":"Genprex, Inc. received a nasdaq deficiency notice notice regarding stockholders equity.","evidence_excerpt":"August 19, 2025, the Company received a notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, the Company was not in compliance with the Minimum Stockholders’ Equity Requirement and as previously disclosed, on August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-25-031210","anchor_url":"https://secwatch.observer/filing/0001437749-25-031210#claim-50cc24aac74dfda4772112233a837047c46d3599","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"fa8706b5896184713653204b1ca8e47e54dfaac8","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-10-17T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2025-10-31","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-10-17","notice_type":"hearing_update","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":[],"rules_cited_in_text":false},"claim":"Genprex, Inc. received a nasdaq hearing update notice regarding minimum bid price.","evidence_excerpt":"received a notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, the Company was not in compliance with the Minimum Stockholders’ Equity Requirement and as previously disclosed, on August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-25-031210","anchor_url":"https://secwatch.observer/filing/0001437749-25-031210#claim-fa8706b5896184713653204b1ca8e47e54dfaac8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"1d3b9ca4b8087f35be9b75eb76b6584255110772","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-10-17T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00 per share","notice_date":"2025-08-12","notice_type":"compliance_regained","plan_due_date":null,"raw_rule_text":"forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) and the minimum stockholders’","reported_value":null,"rule_numbers":["5550(a)(2)","5550(b)(1)"],"rules_cited_in_text":true},"claim":"Genprex, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(1)).","evidence_excerpt":"August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing with the Panel. The Company timely requested a hearing before the Panel, which was held on September 18, 2025.","confidence":0.82,"filing_url":"https://secwatch.observer/filing/0001437749-25-031210","anchor_url":"https://secwatch.observer/filing/0001437749-25-031210#claim-1d3b9ca4b8087f35be9b75eb76b6584255110772","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"6693bb1865118b1c5aa593742cecaebfb3257cdc","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-08-20T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"2500000","notice_date":"2025-08-19","notice_type":"noncompliance_notice","plan_due_date":null,"raw_rule_text":"Listing Rule 5550(b)(1)","reported_value":"1391195","rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"Genprex, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"August 19, 2025, Genprex, Inc. (“Genprex” or the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”), because the Company’s stockholders’ equity of $1,391,195 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025 was below the required minimum of $2.5 millio","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-25-027451","anchor_url":"https://secwatch.observer/filing/0001437749-25-027451#claim-6693bb1865118b1c5aa593742cecaebfb3257cdc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925027451/0001437749-25-027451-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"290fcae59d3213a5e52785d5c7b8fa2b8ecd875c","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-06-09T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"regained_compliance","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-06-06","notice_type":"compliance_regained","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(b)(1)","reported_value":null,"rule_numbers":["5550(b)(1)","5550(b)(2)","5550(b)(3)"],"rules_cited_in_text":true},"claim":"Genprex, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).","evidence_excerpt":"June 6, 2025, Genprex, Inc. (the “Company”) received a letter (the “June 2025 Compliance Letter”) from the Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) providing written confirmation that the Company has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The June 2025 Compliance Letter was pursuant to a previous letter received on November 19, 2024 (the “November 2024 Notice”) from the Nasd","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-019767","anchor_url":"https://secwatch.observer/filing/0001437749-25-019767#claim-290fcae59d3213a5e52785d5c7b8fa2b8ecd875c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925019767/0001437749-25-019767-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"79bde9f6fa7d713f7576d671250ffbb6316b5d48","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2025-02-12T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-08-06","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-02-07","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"]},"claim":"Genprex, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"February 7, 2025, Genprex, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based upon the closing bid pric","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-003490","anchor_url":"https://secwatch.observer/filing/0001437749-25-003490#claim-79bde9f6fa7d713f7576d671250ffbb6316b5d48","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925003490/0001437749-25-003490-index.htm"},{"fact_type":"executive_change","fact_key":"ea10816bfd","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2024-06-24T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-04","interim":false,"role":"Executive Vice President, General Counsel and Chief Strategy Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Catherine Vaczy resigned as Executive Vice President, General Counsel and Chief Strategy Officer at Genprex, Inc..","evidence_excerpt":"Catherine Vaczy, the Company’s then Executive Vice President, General Counsel and Chief Strategy Officer, notified the Company of her intention to resign.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-021031","anchor_url":"https://secwatch.observer/filing/0001437749-24-021031#claim-ea10816bfd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924021031/0001437749-24-021031-index.htm"},{"fact_type":"executive_change","fact_key":"b700322093","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2024-06-24T23:59:59+00:00","payload":{"action":"confirmed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-05-08","interim":false,"role":"President, Chief Executive Officer and Chief Financial Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Ryan M. Confer changed role as President, Chief Executive Officer and Chief Financial Officer at Genprex, Inc..","evidence_excerpt":"Mr. Confer’s title change to President, Chief Executive Officer and Chief Financial Officer was confirmed","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-021031","anchor_url":"https://secwatch.observer/filing/0001437749-24-021031#claim-b700322093","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924021031/0001437749-24-021031-index.htm"},{"fact_type":"executive_change","fact_key":"c54fcd756f","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-08","interim":false,"role":"Class III director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ryan Confer was appointed as Class III director at Genprex, Inc..","evidence_excerpt":"On May 8, 2024, Mr. Confer was also appointed to the Board as a Class III director to fill the vacancy caused by Mr. Varner’s passing","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-015471","anchor_url":"https://secwatch.observer/filing/0001437749-24-015471#claim-c54fcd756f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924015471/0001437749-24-015471-index.htm"},{"fact_type":"executive_change","fact_key":"305ee05c7a","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-08","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Ryan Confer was appointed as President and Chief Executive Officer at Genprex, Inc..","evidence_excerpt":"the Board appointed Ryan Confer, Chief Financial Officer of Genprex since 2016, to serve as President and Chief Executive Officer of Genprex (in addition to his position as Chief Financial Officer of Genprex), effective immediately","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-015471","anchor_url":"https://secwatch.observer/filing/0001437749-24-015471#claim-305ee05c7a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924015471/0001437749-24-015471-index.htm"},{"fact_type":"executive_change","fact_key":"d627fe040e","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"passed away","action_category":"departure","departure_tone":"abrupt","effective_date":"2024-05-07","interim":false,"role":"President and Chief Executive Officer and Chairman","role_category":"ceo","successor_name":"Ryan Confer","successor_named":true},"claim":"Rodney Varner departed as President and Chief Executive Officer and Chairman at Genprex, Inc..","evidence_excerpt":"Rodney Varner, the Company’s President and Chief Executive Officer and Chairman of the Company’s Board of Directors (the “Board”), passed away unexpectedly on May 7, 2024 due to complications from an ongoing illness.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-015471","anchor_url":"https://secwatch.observer/filing/0001437749-24-015471#claim-d627fe040e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924015471/0001437749-24-015471-index.htm"},{"fact_type":"material_agreement","fact_key":"5c2649b47aefa25f4fd04341d49f27a1303fd305","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2024-03-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"an institutional investor","effective_date":"2024-03-19","item_codes_triggered":["1.01"],"value_text":"approximately $5.8 million"},"claim":"Genprex, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $5.8 million (effective 2024-03-19).","evidence_excerpt":"On March 19, 2024, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-008592","anchor_url":"https://secwatch.observer/filing/0001437749-24-008592#claim-5c2649b47aefa25f4fd04341d49f27a1303fd305","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924008592/0001437749-24-008592-index.htm"},{"fact_type":"executive_change","fact_key":"1de56e91fe","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2024-02-05T23:59:59+00:00","payload":{"action":"designated","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Ryan Confer changed role as Chief Financial Officer at Genprex, Inc..","evidence_excerpt":"the Board has determined that Mr. Confer can and shall act alone in covering when Mr. Varner is unavailable.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-003055","anchor_url":"https://secwatch.observer/filing/0001437749-24-003055#claim-1de56e91fe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/0001437749-24-003055-index.htm"},{"fact_type":"executive_change","fact_key":"de600403d1","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2024-02-05T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2024-02-04","interim":false,"role":"Executive Vice President, General Counsel and Chief Strategy Officer","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Catherine Vaczy resigned as Executive Vice President, General Counsel and Chief Strategy Officer at Genprex, Inc..","evidence_excerpt":"Catherine Vaczy, the Executive Vice President, General Counsel and Chief Strategy Officer of Genprex, Inc. (“Genprex” or the “Company”) notified the Company of her intention to resign.  On February 4, 2024, Ms. Vaczy’s employment with the Company was terminated.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-003055","anchor_url":"https://secwatch.observer/filing/0001437749-24-003055#claim-de600403d1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924003055/0001437749-24-003055-index.htm"},{"fact_type":"executive_change","fact_key":"e74a612adb","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2024-02-02T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":null,"role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Catherine Vaczy resigned as other_named_officer at Genprex, Inc..","evidence_excerpt":"On January 30, 2024, Catherine Vaczy provided Genprex, Inc. (“Genprex” or the “Company”) with a notice of her intention to resign pursuant to Section 7.4 of her Executive Employment Agreement","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001437749-24-002878","anchor_url":"https://secwatch.observer/filing/0001437749-24-002878#claim-e74a612adb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924002878/0001437749-24-002878-index.htm"},{"fact_type":"governance_change","fact_key":"facfd46e6202e83e3f36beb6b15e709067e55200","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2024-01-31T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-02-02","item_codes_triggered":["5.03"],"summary_text":"Effected a one-for-forty reverse stock split of common stock via a Certificate of Amendment to the Amended and Restated Certificate of Incorporation."},"claim":"Genprex, Inc.: Effected a one-for-forty reverse stock split of common stock via a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2024-02-02).","evidence_excerpt":"On January 31, 2024, Genprex, Inc. (the “ Company ”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware (the “ Certificate of Amendment ”), which will effect, at 12:01 a.m. Eastern Time on February 2, 2024, a one-for-forty (1:40) reverse stock split","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-002620","anchor_url":"https://secwatch.observer/filing/0001437749-24-002620#claim-facfd46e6202e83e3f36beb6b15e709067e55200","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924002620/0001437749-24-002620-index.htm"},{"fact_type":"shareholder_vote","fact_key":"cb60ef34ed0061404eeaf23668d17d6d3a7e35fd","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2023-12-18T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-14","outcome":"passed","proposal_text":"Amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split","proposal_type":"reverse_split","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"92,628","votes_against":"13,716,034","votes_for":"16,933,367","votes_withheld":null}]},"claim":"Genprex, Inc. shareholders approved Amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split at the 2023-12-14 meeting.","evidence_excerpt":"On December 14, 2023, Genprex, Inc., a Delaware corporation (“we” or “our” or the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). The final voting results for each of the matters submitted to a vote of stockholders at the Special Meeting, as set forth in the Company’s Definitive Proxy Statement, filed with the Securities and Exchange Commission on November 3, 2023, are as follows: Proposal 1. Amendment to our Amended and Restated Certificate of Incorporation . The amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our issued shares of common stock, at a specific ratio, ranging from one-for-ten (1:10) to one-for-fifty (1:50), at any time prior to December 31, 2025, subject to our Board of Directors' determination, in its sole discretion, whether or not to implement the reverse stock split and, if so, at what specific ratio within the foregoing range, without further approval or authorization of our stockholder","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-034760","anchor_url":"https://secwatch.observer/filing/0001437749-23-034760#claim-cb60ef34ed0061404eeaf23668d17d6d3a7e35fd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923034760/0001437749-23-034760-index.htm"},{"fact_type":"material_agreement","fact_key":"e6b012e114d745d956bd1dd27b784946e318a2a7","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2023-12-13T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Equity Distribution Agreement","agreement_type":"atm_program","counterparty":"JMP Securities LLC","effective_date":"2023-12-12","item_codes_triggered":["1.02"],"value_text":null},"claim":"Genprex, Inc. terminated Equity Distribution Agreement with JMP Securities LLC (effective 2023-12-12).","evidence_excerpt":"On December 12, 2023, the Company provided notice of its termination of the Equity Distribution Agreement, dated as of November 18, 2022 (the “Equity Distribution Agreement”), by and between the Company and JMP Securities LLC.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-034341","anchor_url":"https://secwatch.observer/filing/0001437749-23-034341#claim-e6b012e114d745d956bd1dd27b784946e318a2a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923034341/0001437749-23-034341-index.htm"},{"fact_type":"material_agreement","fact_key":"d339ac1352ada8371e7acb4129c64c8d9d545ae4","cik":1595248,"ticker":"GNPX","company_name":"Genprex, Inc.","filed_at":"2023-12-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"At The Market Offering Agreement","agreement_type":"atm_program","counterparty":"H.C. Wainwright & Co., LLC","effective_date":"2023-12-13","item_codes_triggered":["1.01"],"value_text":"up to $25.0 million"},"claim":"Genprex, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $25.0 million (effective 2023-12-13).","evidence_excerpt":"On December 13, 2023, Genprex, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC, serving as agent (the “Agent”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $25.0 million (the “Shares”) through the Agent (the “Offering”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-23-034341","anchor_url":"https://secwatch.observer/filing/0001437749-23-034341#claim-d339ac1352ada8371e7acb4129c64c8d9d545ae4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774923034341/0001437749-23-034341-index.htm"}]}